Advertisement

Alternative Interacting Sites and Novel Receptors for Cannabinoid Ligands

  • Attila Köfalvi

The previous chapters provided us with detailed reviews on the molecular biology and pharmacology of major endocannabinoid and endovanilloid ligands (namely, anandamide and 2-arachidonoylglycerol) and their receptors (CB1, CB2 and TRPV1 receptors), which altogether can be termed as “canonical knowledge”. Still, experimental findings often display mismatches with this canonical knowledge: in the last decade, a rapidly increasing number of studies have reported “non-canonical”, “unusual” pharmacological profiles for certain cannabinoid ligands and receptors. Furthermore, from time to time results are explained by suggesting the involvement of a “new receptor”. The present chapter attempts to give a helpful guideline about how to evaluate “non-canonical” results in the cannabinoid field. All the major topics of “non-canonical” cannabinoid pharmacology, namely interactions of endogenous and exogenous cannabinoid and vanilloid ligands with (1) CB1 receptor splice variants, (2) CB1 receptor heterodimers and other non-ionotropic receptors, (3) ligand- and voltagegated ion channels and finally, (4) neurotransmitter uptake systems are thoroughly reviewed. For sake of simplicity, studies reporting unknown cannabinoid receptors without sufficient investigation of other already defined targets are not discussed here. Finally, this review highlights that the “unorthodox sites of action” may be an unavoidable consequence of evolution, providing novel ideas and pharmaceutical targets to modulate signaling systems in neuropsychiatric disorders.

Keywords

Glycine Receptor Small Mesenteric Artery Adenylyl Cyclase Type nACh Receptor Receptor Splice Variant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akinshola BE, Taylor RE, Ogunseitan AB, Onaivi ES (1999) Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP. Naunyn Schmiedebergs Arch Pharmacol 360:242–248.PubMedCrossRefGoogle Scholar
  2. Aller MI, Veale EL, Linden AM, Sandu C, Schwaninger M, Evans LJ, Korpi ER, Mathie A, Wisden W, Brickley SG (2005) Modifying the subunit composition of TASK channels alters the modulation of a leak conductance in cerebellar granule neurons. J Neurosci 25:11455–11467.PubMedCrossRefGoogle Scholar
  3. Ambrosio AL, Dias SM, Polikarpov I, Zurier RB, Burstein SH, Garratt RC (2007) Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferatoractivatedreceptor gamma. J Biol Chem doi/10.1074/jbc.M702538200.Google Scholar
  4. Baker D, Pryce G, Davies WL, Hiley CR (2006) In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27:1–4.PubMedCrossRefGoogle Scholar
  5. Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M (2002) Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137:589–596.PubMedCrossRefGoogle Scholar
  6. Bátkai S, Pacher P, Járai Z, Wagner JA, Kunos G (2004) Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol 287:H595–H600.PubMedCrossRefGoogle Scholar
  7. Begg M, Mo FM, Offertaler L, Batkai S, Pacher P, Razdan RK, Lovinger DM, Kunos G (2003) G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+current. J Biol Chem 278:46188–46194.PubMedCrossRefGoogle Scholar
  8. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, Liu J, Kunos G (2005) Evidence for novel cannabinoid receptors. Pharmacol Ther 106:133–145.PubMedCrossRefGoogle Scholar
  9. Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, Schulte G, Ernfors P, Mackie K, Paratcha G, Hurd YL, Harkany T (2005) Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci USA 102:19115–191120.PubMedCrossRefGoogle Scholar
  10. Brandes RP, Popp R, Ott G, Bredenkotter D, Wallner C, Busse R, Fleming I (2002) The extracellular regulated kinases (ERK) 1/2 mediate cannabinoid-induced inhibition of gap junctional communication in endothelial cells. Br J Pharmacol 136:709–716.PubMedCrossRefGoogle Scholar
  11. Brown AJ, Wise A (2001) Identification of modulators of GPR55 activity. Patent Number WO0186305.Google Scholar
  12. Brown SP, Safo PK, Regehr WG (2004) Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels. J Neurosci 24:5623–5631.PubMedCrossRefGoogle Scholar
  13. Burstein S (2005) PPAR-B: A nuclear receptor with affinity for cannabinoids. Life Sci 77:1674–1684.PubMedCrossRefGoogle Scholar
  14. Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A, Müller C, Woods AS, Hope BT, Ciruela F, Casadó V, Canela EI, Lluis C, Goldberg SR, Moratalla R, Franco R, Ferré S (2007) Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacol doi:10.1038/sj.npp. 1301375.Google Scholar
  15. Cheer JF, Cadogan AK, Marsden CA, Fone KC, Kendall DA (1999) Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38:533–541.PubMedCrossRefGoogle Scholar
  16. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P (2001) Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J 20:7033–7040.PubMedCrossRefGoogle Scholar
  17. Chen N, Appell M, Berfield JL, Reith ME (2003) Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporter. Eur J Pharmacol 478:89–95.PubMedCrossRefGoogle Scholar
  18. Christopoulos A, Wilson K (2001) Interaction of anandamide with the M1 and M4 muscarinic acetylcholine receptors. Brain Res 915:70–78.PubMedCrossRefGoogle Scholar
  19. Cunha RA (2001) Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem Int 38:107–125.PubMedCrossRefGoogle Scholar
  20. Deadwyler SA, Hampson RE, Mu J, Whyte A, Childers S (1995) Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther 273:734–743.PubMedGoogle Scholar
  21. del Carmen Godino M, Torres M, Sanchez-Prieto J (2005) The modulation of Ca2+ and K+ channels, but not changes in cAMP, signaling contribute to the inhibition of glutamate release by cannabinoid receptors in cerebrocortical nerve terminals. Neuropharmacology 48:547–557.PubMedCrossRefGoogle Scholar
  22. Devlin MG, Christopoulos A (2002) Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. J Neurochem 80:1095–1102.PubMedCrossRefGoogle Scholar
  23. Docherty RJ, Yeats JC, Piper AS (1997) Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture. Br J Pharmacol 121:1461–1467.PubMedCrossRefGoogle Scholar
  24. Drebot II, Storozhuk MV, Kostyuk PG (2006) An unexpected effect of capsaicin on spontaneous GABAergic IPSCs in hippocampal cell cultures. Neurophysiology 38:364–367.CrossRefGoogle Scholar
  25. Duarte JM, Nogueira C, Mackie K, Oliveira CR, Cunha RA, Köfalvi A. Increase of cannabinoid CB1 receptor density in the hippocampus of streptozotocin-induced diabetic rats. Exp Neurol 204:479–484.Google Scholar
  26. Elphick MR, Egertová M (2005) The phylogenetic distribution and evolutionary origins of endocannabinoid signalling. Handbook Exp Pharmacol 168:283–297.CrossRefGoogle Scholar
  27. Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, Schwartz A, Snutch TP, Tanabe T, Birnbaumer L, Tsien RW, Catterall WA (2000) Nomenclature of voltage-gated calcium channels. Neuron 25:533–555.PubMedCrossRefGoogle Scholar
  28. Fan P (1995) Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 73:907–910.PubMedGoogle Scholar
  29. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425:90–93.PubMedCrossRefGoogle Scholar
  30. Garcia-Anoveros J, Nagata K (2007) TRPA1. Handbook Exp Pharmacol 179:347–362.CrossRefGoogle Scholar
  31. Gill CH, Randall A, Bates SA, Hill K, Owen D, Larkman PM, Cairns W, Yusaf SP, Murdock PR, Strijbos PJ, Powell AJ, Benham CD, Davies CH (2004) Characterization of the human HCN1 channel and its inhibition by capsazepine. Br J Pharmacol 143:411–421.PubMedCrossRefGoogle Scholar
  32. Glass M, Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327–5333.PubMedGoogle Scholar
  33. Glass M, Northup JK (1999) Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Mol Pharmacol 56:1362–1369.PubMedGoogle Scholar
  34. Godlewski G, Gothert M, Malinowska B (2003) Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex. Br J Pharmacol 138:767–774.PubMedCrossRefGoogle Scholar
  35. Gothert M, Bruss M, Bonisch H, Molderings GJ (1999) Presynaptic imidazoline receptors. New developments in characterization and classification. Ann N Y Acad Sci 881:171–184.PubMedCrossRefGoogle Scholar
  36. Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, Leonoudakis DJ, Bickler PE (1998) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 70:671–676.PubMedCrossRefGoogle Scholar
  37. Harkány T, Guzmán M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K (2007) The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 28:83–92.PubMedCrossRefGoogle Scholar
  38. Hart S, Fischer OM, Ullrich A (2004) Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64:1943–1950.PubMedCrossRefGoogle Scholar
  39. Hejazi N, Zhou C, Oz M, Sun H, Ye JH, Zhang L (2005) Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol Pharmacol 69:991–997.PubMedGoogle Scholar
  40. Ho WS, Hiley CR (2003) Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol 138:1320–1332.PubMedCrossRefGoogle Scholar
  41. Ho WS, Hiley CR (2004) Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. J Pharm Pharmacol 56:869–875.PubMedCrossRefGoogle Scholar
  42. Hogestatt ED, Jonsson BA, Ermund A, Andersson DA, Bjork H, Alexander JP, Cravatt BF, Basbaum AI, Zygmunt PM (2005) Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280:31405–31412.PubMedCrossRefGoogle Scholar
  43. Hoi PM, Hiley CR (2006) Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol 147:560–568.PubMedCrossRefGoogle Scholar
  44. Jarrahian A, Watts VJ, Barker EL (2004) D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 308:880–886.PubMedCrossRefGoogle Scholar
  45. Jeske NA, Patwardhan AM, Gamper N, Price TJ, Akopian AN, Hargreaves KM (2006) Cannabinoid WIN 55, 212–2 regulates TRPV1 phosphorylation in sensory neurons. J Biol Chem 281:32879–32890.PubMedCrossRefGoogle Scholar
  46. Johnson DE, Heald SL, Dally RD, Janis RA (1993) Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1, 4-dihydropyridine binding. Prostaglandins, Leukotrienes and Essential Fatty Acids 48:429–437.CrossRefGoogle Scholar
  47. Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Hogestatt ED, Meng ID, Julius D (2004) Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427:260–265.PubMedCrossRefGoogle Scholar
  48. Kathmann M, Flau K, Redmer A, Trankle C, Schlicker E (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. N Schmied Arch Pharmacol 372:354–361.CrossRefGoogle Scholar
  49. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M (2004) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67:1697–1704.CrossRefGoogle Scholar
  50. Kelley BG, Thayer SA (2004) Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors. Eur J Pharmacol 496:33–39.PubMedCrossRefGoogle Scholar
  51. Kim HI, Kim TH, Shin YK, Lee CS, Park M, Song JH (2005) Anandamide suppression of Na+ currents in rat dorsal root ganglion neurons. Brain Res 1062:39–47.PubMedCrossRefGoogle Scholar
  52. Köfalvi A, Vizi ES, Ledent C, Sperlágh B (2003) Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. Eur J Neurosci 18:1973–1978.PubMedCrossRefGoogle Scholar
  53. Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlágh B (2005) Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 25:2874–2884.PubMedCrossRefGoogle Scholar
  54. Köfalvi A, Oliveira CR, Cunha RA (2006a) Lack of evidence for functional TRPV1 vanilloid receptors in rat hippocampal nerve terminals. Neurosci Lett 403:151–156.PubMedCrossRefGoogle Scholar
  55. Köfalvi A, Rebola N, Rodrigues RJ, Pereira MF, Cunha RA (2006b) Evidence for CB1Rs, but lack of evidence for presynaptic functional CB2Rs and TRPV1Rs in the hippocampus. Annual International Cannabinoid Research Society Meeting, Tihany, Hungary.Google Scholar
  56. Köfalvi A, Pereira MF, Rebola N, Rodrigues RJ, Oliveira CR, Cunha RA (2007) Anandamide and NADA bi-directionally modulate presynaptic Ca2+ levels and transmitter release in the hippocampus. Br J Pharmacol doi:10.1038/sj.bjp. 0707252.Google Scholar
  57. Kozak KR, Gupta RA, Moody JS, Ji C, Boeglin WE, DuBois RN, Brash AR, Marnett LJ (2002) 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem 277:23278–23286.PubMedCrossRefGoogle Scholar
  58. Lagalwar S, Bordayo EZ, Hoffmann KL, Fawcett JR, Frey WH II (1999) Anandamides inhibit binding to the muscarinic acetylcholine receptor. J Mol Neurosci 13:55–61.PubMedCrossRefGoogle Scholar
  59. Lauckner JE, Hille B, Mackie K (2005) The cannabinoid agonist WIN55, 212–2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci USA 102:19144–19149.PubMedCrossRefGoogle Scholar
  60. Lawson K (2000) Is there a role for potassium channel openers in neuronal ion channel disorders? Expert Opin Investig Drugs 9:2269–2280.PubMedCrossRefGoogle Scholar
  61. Lesage F, Lazdunski M (2000) Molecular and functional properties of two-pore-domain potassium channels. Am J Physiol Renal Physiol 279:F793–801.PubMedGoogle Scholar
  62. Liao C, Zheng J, David LS, Nicholson RA (2004) Inhibition of voltage-sensitive sodium channels by the cannabinoid 1 receptor antagonist AM 251 in mammalian brain. Basic Clin Pharmacol Toxicol 94:73–78.PubMedGoogle Scholar
  63. Linden AM, Aller MI, Leppa E, Vekovischeva O, Aitta-Aho T, Veale EL, Mathie A, Rosenberg P, Wisden W, Korpi ER (2006) The in vivo contributions of TASK-1-containing channels to the actions of inhalation anesthetics, the alpha2 adrenergic sedative dexmedetomidine, and cannabinoid agonists. J Pharmacol Exp Ther 317:615–626.PubMedCrossRefGoogle Scholar
  64. Liu J, Li H, Burstein SH, Zurier RB, Chen JD (2003) Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 63:983–992.PubMedCrossRefGoogle Scholar
  65. Liu L, Simon SA (1997) Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia. Neurosci Lett 228:29–32.PubMedCrossRefGoogle Scholar
  66. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15–19.PubMedCrossRefGoogle Scholar
  67. Lozovaya N, Yatsenko N, Beketov A, Tsintsadze T, Burnashev N (2005) Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids. J Neurosci 25:7499–7506.PubMedCrossRefGoogle Scholar
  68. Lundbaek JA, Birn P, Tape SE, Toombes GE, Sogaard R, Koeppe RE 2nd, Gruner SM, Hansen AJ, Andersen OS (2005) Capsaicin regulates voltage-dependent sodium channels by altering lipid bilayer elasticity. Mol Pharmacol 68:680–689.PubMedGoogle Scholar
  69. Mackie K (2005) Cannabinoid receptor homo- and heterodimerization. Life Sci 77:1667–1673.PubMedCrossRefGoogle Scholar
  70. Mackie K, Stella N (2006) Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8:E298–306.PubMedGoogle Scholar
  71. Mackie K, Lai Y, Wenstenbroek R, Mitchell R (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in At20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15:6552–6561.PubMedGoogle Scholar
  72. Maingret F, Patel AJ, Lazdunski M, Honore E (2001) The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1. EMBO J 20:47–54.PubMedCrossRefGoogle Scholar
  73. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D (1991) Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 254:432–437.PubMedCrossRefGoogle Scholar
  74. Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF (2006) Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137:337–361.PubMedCrossRefGoogle Scholar
  75. McPartland JM, Glass M (2003) Functional mapping of cannabinoid receptor homologs in mammals, other vertebrates, and invertebrates. Gene 312:297–303.PubMedCrossRefGoogle Scholar
  76. McPartland JM, Matias I, Di Marzo V, Glass M (2006) Evolutionary origins of the endocannabinoid system. Gene 370:64–74.PubMedCrossRefGoogle Scholar
  77. Molderings GJ, Likungu J, Gothert M (1999) Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. N Schmied Arch Pharmacol 360:157–164.CrossRefGoogle Scholar
  78. Molderings GJ, Bonisch H, Hammermann R, Gothert M, Bruss M (2002) Noradrenaline release-inhibiting receptors on PC12 cells devoid of alpha2- and CB1 receptors: similarities to presynaptic imidazoline and edg receptors. Neurochem Int 40:157–167.PubMedCrossRefGoogle Scholar
  79. Morales M, Backman C (2002) Coexistence of serotonin 3 (5-HT3) and CB1 cannabinoid receptors in interneurons of hippocampus and dentate gyrus. Hippocampus 12:756–764.PubMedCrossRefGoogle Scholar
  80. Moran MM, Xu H, Clapham DE (2004) TRP ion channels in the nervous system. Curr Opin Neurobiol 14:362–369.PubMedCrossRefGoogle Scholar
  81. Nicholson RA, Liao C, Zheng J, David LS, Coyne L, Errington AC, Singh G, Lees G (2003) Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res 978:194–204.PubMedCrossRefGoogle Scholar
  82. Nilius B, Vriens J, Prenen J, Droogmans G, Voets T (2004) TRPV4 calcium entry channel: a paradigm for gating diversity. Am J Physiol Cell Physiol 286:C195–205.PubMedCrossRefGoogle Scholar
  83. Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK, Martin BR, Bukoski RD, Kunos G (2003) Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63:699–705.PubMedCrossRefGoogle Scholar
  84. Ohno-Shosaku T, Matsui M, Fukudome Y, Shosaku J, Tsubokawa H, Taketo MM, Manabe T, Kano M (2003) Postsynaptic M1 and M3 receptors are responsible for the muscarinic enhancement of retrograde endocannabinoid signalling in the hippocampus. Eur J Neurosci 18:109–116.PubMedCrossRefGoogle Scholar
  85. Oliver D, Lien CC, Soom M, Baukrowitz T, Jonas P, Fakler B (2004) Functional conversion between A-type and delayed rectifier K+ channels by membrane lipids. Science 304:265–270.PubMedCrossRefGoogle Scholar
  86. O’Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD (2005) Novel time-dependent vascular actions of O9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 337:824–831.PubMedCrossRefGoogle Scholar
  87. Oz M (2006) Receptor-independent effects of endocannabinoids on ion channels. Curr Pharm Des 12:227–329.PubMedCrossRefGoogle Scholar
  88. Oz M, Tchugunova Y, Dunn SMJ (2000) Endogenous cannabinoid anandamide directly inhibits voltage- dependent calcium fluxes in rabbit T-tubule membrane preparations. Eur J Pharmacol 404:13–20.PubMedCrossRefGoogle Scholar
  89. Oz M, Zhang L, Morales M (2002) Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes. Synapse 46:150–156.PubMedCrossRefGoogle Scholar
  90. Oz M, Ravindran R, Zhang L, Morales M (2003) Endogenous cannabinoid, anandamide inhibits neuronal nicotinic acethylcholine receptor-mediated responses in Xenopus oocytes. J Pharmacol Exp Ther 306:1003–1010.PubMedCrossRefGoogle Scholar
  91. Oz M, Tchugunova Y, Dinc M (2004a) Differential effects of endogenous and synthetic cannabinoids on voltage-dependent calcium fluxes in rabbit T-tubule membranes: comparison with fatty acids. Eur J Pharmacol 502:47–58.PubMedCrossRefGoogle Scholar
  92. Oz M, Zhang L, Ravindran A, Morales M, Lupica CR (2004b) Differential effects of endogenous and synthetic cannabinoids on alpha7-nicotinic acetylcholine receptor-mediated responses in Xenopus Oocytes. J Pharmacol Exp Ther 310:1152–1160.PubMedCrossRefGoogle Scholar
  93. Oz M, Jackson SN, Woods AS, Morales M, Zhang L (2005) Additive effects of endogenous cannabinoid anandamide and ethanol on alpha7-nicotinic acetylcholine receptor-mediated responses in Xenopus Oocytes. J Pharmacol Exp Ther 313:1272–1280.PubMedCrossRefGoogle Scholar
  94. Pearlman RJ, Aubrey KR, Vandenberg RJ (2003) Arachidonic acid and anandamide have opposite modulatory actions at the glycine transporter, GLYT1a. J Neurochem 84:592–601.PubMedCrossRefGoogle Scholar
  95. Pedersen SF, Owsianik G, Nilius B (2005) TRP channels: an overview. Cell Calcium 38:233–252.PubMedCrossRefGoogle Scholar
  96. Pereira DB, Rebola N, Rodrigues RJ, Cunha RA, Carvalho AP, Duarte CB (2006) Trkb receptors modulation of glutamate release is limited to a subset of nerve terminals in the adult rat hippocampus. J Neurosci Res 83:832–844.PubMedCrossRefGoogle Scholar
  97. Pertwee RG (2004) Novel pharmacological targets for cannabinoids. Curr Neuropharmacol 2:9–29.CrossRefGoogle Scholar
  98. Pertwee RG (2005) Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168:1–51.PubMedCrossRefGoogle Scholar
  99. Poling JS, Rogawski MA, Salem N Jr, Vicini S (1996) Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels. Neuropharmacology 35:983–991.PubMedCrossRefGoogle Scholar
  100. Prather PL, Martin NA, Breivogel CS, Childers SR (2000) Activation of cannabinoid receptors in rat brain by WIN 55212–2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol Pharmacol 57:1000–1010.PubMedGoogle Scholar
  101. Price DA, Owens WA, Gould GG, Frazer A, Roberts JL, Daws LC, Giuffrida A (2007) CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J Neurochem doi:10.1111/j.1471–4159.2006.04383.x.Google Scholar
  102. Puntambekar P, Van Buren J, Raisinghani M, Premkumar LS, Ramkumar V (2004) Direct interaction of adenosine with the TRPV1 channel protein. J Neurosci 24:3663–3671.PubMedCrossRefGoogle Scholar
  103. Rao GK, Kaminski NE (2006a) Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. J Pharmacol Exp Ther 317:820–829.PubMedCrossRefGoogle Scholar
  104. Rao GK, Kaminski NE (2006b) Induction of intracellular calcium elevation by Delta9-tetrahydrocannabinol in T cells involves TRPC1 channels. J Leukoc Biol 79:202–213.PubMedCrossRefGoogle Scholar
  105. Rawls SM, Tallarida RJ, Zisk J (2006) Agmatine and a cannabinoid agonist, WIN 55212–2, interact to produce a hypothermic synergy. Eur J Pharmacol 553:89–98.PubMedCrossRefGoogle Scholar
  106. Rhee M-H, Bayewitch ML, Avidor-Reiss T, Levy R and Vogel Z (1998) Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem 71:1525–1534.PubMedGoogle Scholar
  107. Rhee MH, Nevo I, Avidor-Reiss T, Levy R, Vogel Z (2000) Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB1 cannabinoid receptor. Mol Pharmacol 57:746–552.PubMedGoogle Scholar
  108. Rios C, Gomes I, Devi LA (2006) mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148:387–395.PubMedCrossRefGoogle Scholar
  109. Robinson RB, Siegelbaum SA (2003) Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol 65:453–480.PubMedCrossRefGoogle Scholar
  110. Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE (2006) Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 70:101–111.PubMedGoogle Scholar
  111. Rothlin CV, Katz E, Verbitsky M, Elgoyhen AB (1999) The alpha9 nicotinic acetylcholine receptor shares pharmacological properties with type A gamma-aminobutyric acid, glycine, and type 3 serotonin receptors. Mol Pharmacol 55:248–254.PubMedGoogle Scholar
  112. Ryberg E, Vu HK, Larsson N, Groblewski T, Hjorth S, Elebring T, Sjogren S, Greasley PJ (2005) Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett 579:259–264.PubMedCrossRefGoogle Scholar
  113. Sade H, Muraki K, Ohya S, Hatano N, Imaizumi Y (2006) Activation of large-conductance, Ca2+-activated K+ channels by cannabinoids. Am J Physiol Cell Physiol 290:C77–C86.PubMedCrossRefGoogle Scholar
  114. Saghatelian A, McKinney MK, Bandell M, Patapoutian A, Cravatt BF (2006) A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 45:9007–9015.PubMedCrossRefGoogle Scholar
  115. Salzet M, Stefano GB (2002) The endocannabinoid system in invertebrates. Prostaglandins, Leukotrienes and Essential Fatty Acids 66:353–361.CrossRefGoogle Scholar
  116. Savinainen JR, Saario SM, Niemi R, Jarvinen T, Laitinen JT (2003) An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 140:1451–1459.PubMedCrossRefGoogle Scholar
  117. Schild L (2004) The epithelial sodium channel: from molecule to disease. Rev Physiol Biochem Pharmacol 151:93–107.PubMedCrossRefGoogle Scholar
  118. Schoffelmeer AN, Hogenboom F, Wardeh G, De Vries TJ (2006) Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51:773–781.PubMedCrossRefGoogle Scholar
  119. Seth P, Cheeta S, Tucci S, File SE (2002) Nicotinic-serotonergic interactions in brain and behaviour. Pharmacol Biochem Behav 71:795–805.PubMedCrossRefGoogle Scholar
  120. Shen M, Thayer SA (1998) The cannabinoid agonist Win55, 212–2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res 783:77–84.PubMedCrossRefGoogle Scholar
  121. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Caput D, Ferrara P (1995) An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 270:3726–3731.PubMedCrossRefGoogle Scholar
  122. Steffens M, Feuerstein TJ (2004) Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex - involvement of Na+/K+-ATPase. Neurochem Int 44:529–538.PubMedCrossRefGoogle Scholar
  123. Su JY, Vo AC (2007) 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling. Eur J Pharmacol 559:189–195.PubMedCrossRefGoogle Scholar
  124. Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, Takayama H, Waku K, Seki C, Baba N, Ishima Y (1999) Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem 274:2794–2801.PubMedCrossRefGoogle Scholar
  125. Tapia R, Velasco I (1997) Ruthenium red as a tool to study calcium channels, neuronal death and the function of neural pathways. Neurochem Int 30:137–147.PubMedCrossRefGoogle Scholar
  126. Trevisani M, Smart D, Gunthorpe MJ, Tognetto M, Barbieri M, Campi B, Amadesi S, Gray J, Jerman JC, Brough SJ, Owen D, Smith GD, Randall AD, Harrison S, Bianchi A, Davis JB, Geppetti P (2002) Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat Neurosci 5:546–551.PubMedCrossRefGoogle Scholar
  127. Upham BL, Rummel AM, Carbone JM, Trosko JE, Ouyang Y, Crawford RB, Kaminski NE (2003) Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. Int J Cancer 104:12–18.PubMedCrossRefGoogle Scholar
  128. Van den Bossche I, Vanheel B (2000) Influence of cannabinoids on the delayed rectifier in freshly dissociated smooth muscle cells of the rat aorta. Br J Pharmacol 131:85–93.PubMedCrossRefGoogle Scholar
  129. van der Stelt M, Di Marzo V (2005) Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins and other Lipid Mediators 77:111–122.PubMedCrossRefGoogle Scholar
  130. Venance L, Piomelli D, Glowinski J, Giaume C (1995) Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 376:590–594.PubMedCrossRefGoogle Scholar
  131. Vigano D, Rubino T, Parolaro D (2005) Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 81:360–368.PubMedCrossRefGoogle Scholar
  132. White R, Hiley CR (1998) The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br J Pharmacol 125:689–696.PubMedCrossRefGoogle Scholar
  133. Williams EJ, Walsh FS, Doherty P (2003) The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J Cell Biol 160:481–486.PubMedCrossRefGoogle Scholar
  134. Yamamura H, Ugawa S, Ueda T, Nagao M, Shimada S (2004) Capsazepine is a novel activator of the delta subunit of the human epithelial Na+channel. J Biol Chem 279:44483–44489.PubMedCrossRefGoogle Scholar
  135. Zhao Q, He Z, Chen N, Cho YY, Zhu F, Lu F, Ma WY, Bode AM, Dong Z (2005) 2-Arachidonoylglycerol stimulates activator protein-1-dependent transcriptional activity and enhances epidermal growth factor-induced cell transformation in JB6 P+ cells. J Biol Chem 280:26735–26742.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Attila Köfalvi

    There are no affiliations available

    Personalised recommendations